|
| Press Releases |
|
 |
|
| Wednesday, November 27, 2024 |
|
|
Kingworld-Longde Life and Health Industrial Park Grand Opening |
| Kingworld Medicines Group Limited ("Kingworld Medicines" or the "Group", stock code: 01110.HK), a leading healthcare distribution company, announced that the Group's Kingworld-Longde Life and Health Industrial Park ("Longde Health Industrial Park" or "Industrial Park") in Bao'an Technology City, Longgang District, Shenzhen, has officially commenced operations. more info >> |
|
|
金活醫藥旗下金活 - 龍德生命健康產業園盛大啟用 |
| 醫藥大健康分銷領先企業—金活醫藥集團有限公司（「金活醫藥」或「集團」，股份代號：01110.HK）欣然公佈，集團位於深圳市龍崗區寶龍工業城的金活·龍德生命健康產業園（「龍德健康產業園」或「產業園」）正式投入使用，開園儀式暨招商大會及投資者參觀圓滿舉行，標誌集團三十週年在醫藥大健康產業領域繼續譜寫新篇章，並為大灣區打造國家級醫藥產業孵化及招商基地。 more info >> |
|
| Monday, August 28, 2023 |
|
|
金活医药中期公司拥有人应占溢利同比增长55.8% |
| 医药大健康分销领先企业—金活医药集团有限公司（「金活医药」或「集团」，股份代号：01110.HK）欣然公布其截至2023年6月30日止六个月(「报告期内」或「上半年」)未经审核之中期业绩。 more info >> |
|
|
Net Profit of Kingworld Medicines Increased By 55.8% |
| Kingworld Medicines Group Limited ("Kingworld Medicines" or the "Group", stock code: 01110.HK), a leading healthcare distribution company, announced its unaudited interim results for the year ended 30 June 2023 (the "Reporting Period" or the "First Half of 2023") . more info >> |
|
|
金活醫藥中期公司擁有人應占溢利同比增長55.8% |
| 醫藥大健康分銷領先企業—金活醫藥集團有限公司（「金活醫藥」或「集團」，股份代號：01110.HK）欣然公佈其截至2023年6月30日止六個月(「報告期內」或「上半年」)未經審核之中期業績。 more info >> |
|
| Wednesday, August 16, 2023 |
|
|
金活医药优化产业布局 进一步认购大幸药业2.08%股权 |
| 医药大健康分销领先企业—金活医药集团有限公司（「金活医药」或「集团」，股份代号：01110.HK）于15日公布，金活医药将进一步认购日本大幸药品株式会社（「大幸药品」，股票代码：4574.JP） more info >> |
|
|
金活醫藥優化產業佈局 進一步認購大幸藥業2.08%股權 |
| 醫藥大健康分銷領先企業—金活醫藥集團有限公司（「金活醫藥」或「集團」，股份代號：01110.HK）於15日公佈，金活醫藥將進一步認購日本大幸藥品株式會社（「大幸藥品」，股票代碼：4574.JP） more info >> |
|
|
Kingworld Further Subscribed For 2.08% Equity of Taiko Pharmaceutical To Optimize Its Layout of Pharmaceutical Industry |
| Kingworld Medicines Group Limited ("Kingworld Medicines" or the "Group", stock code: 01110.HK), a leading healthcare distribution company, announced on 15th that the Group plans to further subscribe for the shares of Taiko Pharmaceutical Co., Ltd. more info >> |
|
| Wednesday, August 2, 2023 |
|
|
金活医药预期上半年溢利增长35%至40% |
| 医药大健康分销领先企业—金活医药集团有限公司（「金活医药」或「集团」，股份代号：01110.HK）欣然公布，基于本集团截至2023年6月30日止的未经审核综合管理账目及董事会目前可得的资料之初步评估，预期2023年上半年的溢利将较去年同期增加约35%至40%。 more info >> |
|
|
金活醫藥預期上半年溢利增長35%至40% |
| 醫藥大健康分銷領先企業—金活醫藥集團有限公司（「金活醫藥」或「集團」，股份代號：01110.HK）欣然公布，基於本集團截至2023年6月30日止的未經審核綜合管理賬目及董事會目前可得的資料之初步評估，預期2023年上半年的溢利將較去年同期增加約35%至40%。 more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
珠宝双展匯聚逾82,000环球买家
Mar 9, 2025 13:51 HKT/SGT
|
|
|
珠寶雙展匯聚逾82,000環球買家
Mar 9, 2025 13:41 HKT/SGT
|
|
|
Twin jewellery shows attract over 82,000 global buyers
Mar 9, 2025 13:19 HKT/SGT
|
|
|
OrbusNeich Achieves Fourth Consecutive Year of Revenue Growth with Record High Revenue of US$164.1 Million and Net Profit of US$39.7 Million
Mar 8, 2025 19:40 HKT/SGT
|
|
|
Everest Medicines Hits Three-Year High as AI+mRNA Pipeline Reshapes Valuation
Mar 8, 2025 19:20 HKT/SGT
|
|
|
uSMART Securities Initiates Coverage on NAAS Technology with a 'Buy' Rating and a Target Price of US$3.2 per ADS, Citing Industry Leadership and Profitability Outlook
Mar 7, 2025 21:26: JST
|
|
|
Everest Medicines Hits Three-Year High as AI+mRNA Pipeline Reshapes Valuation
Mar 7, 2025 20:31: JST
|
|
|
uSMART Securities Initiates Coverage on NAAS Technology with a 'Buy' Rating and a Target Price of US$3.2 per ADS, Citing Industry Leadership and Profitability Outlook
Mar 7, 2025 20:26 HKT/SGT
|
|
|
雲頂新耀股價創3年新高 AI+mRNA賦能管線重塑估值
Mar 7, 2025 19:24 HKT/SGT
|
|
|
云顶新耀股价创3年新高 AI+mRNA赋能管线重塑估值
Mar 7, 2025 19:16 HKT/SGT
|
|
|
業聚醫療連續四年實現收入增長 達1.64億美元創新高 純利達3,970萬美元 建議派發末期股息每股10港仙
Mar 7, 2025 18:28 HKT/SGT
|
|
|
业聚医疗连续四年实现收入增长 达1.64亿美元创新高 纯利达3,970万美元 建议派发末期股息每股10港仙
Mar 7, 2025 18:10 HKT/SGT
|
|
|
東信營銷科技：中國AI營銷龍頭斬獲多模態雙備案 技術實力獲國家級認證
Mar 7, 2025 17:58 HKT/SGT
|
|
|
东信营销科技：中国AI营销龙头斩获多模态双备案 技术实力获国家级认证
Mar 7, 2025 17:20 HKT/SGT
|
|
|
Japan's Telecommunications Carriers Enhance Disaster Response with On-site Training for Joint Use of Marine Vessels
Mar 7, 2025 16:24 JST
|
|
|
|
|
More News >> |
|
|
|
|
|
